IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13905

Maria Rosaria Valerio, Giuseppa Scandurra, Martina Greco, Vittorio Gebbia, Dario Piazza, Daniela Sambataro

{"title":"A Survey on the Prescribing Orientation Towards Complementary Therapies Among Oncologists in Italy: Symptoms and Unmet Patient Needs.","authors":"Maria Rosaria Valerio, Giuseppa Scandurra, Martina Greco, Vittorio Gebbia, Dario Piazza, Daniela Sambataro","doi":"10.21873/invivo.13905","DOIUrl":"10.21873/invivo.13905","url":null,"abstract":"Background/aim: A high percentage of cancer patients use complementary therapies (CM) during their disease journey. Several barriers for CM prescription still exist among oncologists. This study explored oncologists' attitudes toward prescribing CM with oral supplements or confirming prescriptions made by others.Materials and methods: The study employed a mixed semi-quantitative and qualitative research strategy via a web-based platform interview as a preliminary step for a program of observational studies on the oncologist's prescriptions of oral supplements in cancer management, in Italy.Results: Out of 95 invited oncologists, 40 participated in the study, mainly working in a general hospital or a cancer center. The deep knowledge of guidelines on integrative medicine was generally poor. The symptoms driving oncologists to initiate discussions on CM with patients were fatigue, anorexia/poor appetite, weight loss, insomnia, distress, neuropathy, or pain. The presence of reliable data in the medical literature on prescribing CM was a significant factor in choosing a supplement.Conclusion: This study reveals that oncologists' limited knowledge and lack of standardized guidelines hinder the prescription of CM, despite recognizing its potential benefits. CM discussions are primarily patient-driven, with prescriptions influenced by reliable scientific data and symptom management. Expanding integrative medicine services and research on CM efficacy could enhance oncologists' confidence, improve patient care, and address unmet needs in oncology.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1000-1008"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13898

Toru Ishikawa, Nanako Terai, Ryo Sato, Hiroki Natsui, Takahiro Iwasawa, Masahiro Ogawa, Yuji Kobayashi, Toshifumi Sato, Junji Yokoyama, Akihiko Iiduka, Terasu Honma

{"title":"Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma.","authors":"Toru Ishikawa, Nanako Terai, Ryo Sato, Hiroki Natsui, Takahiro Iwasawa, Masahiro Ogawa, Yuji Kobayashi, Toshifumi Sato, Junji Yokoyama, Akihiko Iiduka, Terasu Honma","doi":"10.21873/invivo.13898","DOIUrl":"10.21873/invivo.13898","url":null,"abstract":"Background/aim: The combination of atezolizumab and bevacizumab is the standard treatment for hepatocellular carcinoma (HCC). However, cases of portal hypertension (PHT) have been reported with atezolizumab/bevacizumab combination therapy. Splenomegaly caused by PHT may disrupt the immune environment and increase the risk of therapeutic failure with this combination therapy. Partial splenic embolization (PSE) is a treatment option for splenomegaly; however, the usefulness of PSE for PHT during atezolizumab/bevacizumab combination therapy is unclear. This study investigated the effect of PSE on the immune environment in a patient with splenomegaly caused by exacerbation of PHT during atezolizumab/bevacizumab combination therapy for HCC.Patients and methods: Of the 56 patients with unresectable HCC treated with atezolizumab/bevacizumab, four with splenomegaly and progressive disease (PD) underwent PSE.Results: PHT during atezolizumab/bevacizumab combination therapy led to a mean enlargement of the splenic size of 142.7%, an increase in the neutrophil-lymphocyte ratio (NLR), a decrease in lymphocyte counts, and a decrease in platelet counts. PSE increased platelet counts and lymphocyte counts, and decreased the NLR compared with pre-PSE levels. Atezolizumab/bevacizumab combination therapy, which caused PD due to PHT, resulted in a non-PD state with continued treatment after PSE.Conclusion: In patients with PHT receiving atezolizumab/bevacizumab combination therapy, PSE promotes recovery from leukopenia and thrombocytopenia. Furthermore, PSE treatment may also induce host immune activation and boost immunity.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"936-941"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Significance of STK11/LKB1 Expression and Its Role in the Tumor Microenvironment of Colorectal Adenocarcinoma.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13873

Yung-Heng Lee, Chun-Fan Yang, Yih-Farng Liou, Kevin Chih-Yang Huang, K S Clifford Chao, Shu-Fen Chiang

{"title":"Prognostic Significance of STK11/LKB1 Expression and Its Role in the Tumor Microenvironment of Colorectal Adenocarcinoma.","authors":"Yung-Heng Lee, Chun-Fan Yang, Yih-Farng Liou, Kevin Chih-Yang Huang, K S Clifford Chao, Shu-Fen Chiang","doi":"10.21873/invivo.13873","DOIUrl":"10.21873/invivo.13873","url":null,"abstract":"Background/aim: The loss or mutation of serine-threonine kinase 11/liver kinase B1 (STK11/LKB1) is known to negatively impact prognosis and immunotherapy outcomes in non-small cell lung cancer (NSCLC), and germline mutations in this gene cause gastrointestinal adenocarcinomas in patients with Peutz-Jeghers syndrome (PJS). Although STK11/LKB1 mutations are rare in colorectal cancer, the down-regulation of STK11/LKB1 has been implicated in its tumorigenesis. However, the relationship between STK11/LKB1 expression and the immunosuppressive tumor microenvironment in colorectal cancer remains unclear.Materials and methods: In this study, we collected tissues from patients with colorectal adenocarcinoma (COAD) and constructed tissue microarrays (TMAs). STK11/LKB1 expression was assessed by immunohistochemistry and quantified by calculating H-scores. We also examined subsets of intratumoral tumor-infiltrating lymphocytes (TILs), including CD45+, CD8+, PD-1+, and CD45RO+ TILs, in these TMAs.Results: STK11/LKB1 expression was significantly correlated with nodal metastasis. Kaplan-Meier survival analysis demonstrated that low STK11 expression was associated with significantly poorer overall survival (OS), particularly in COAD patients with KRAS mutations. However, STK11/LKB1 expression was not correlated with the presence of intratumoral CD45+, CD8+, PD-1+, or CD45RO+ TILs. Finally, multivariate Cox proportional regression analysis identified STK11/LKB1 expression as an independent prognostic factor in COAD patients.Conclusion: While STK11/LKB1 expression is associated with tumor progression and survival outcomes, there is no evidence that STK11/LKB1 expression influences the infiltration of lymphocytes into the tumor microenvironment.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"691-701"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic Kidney Disease Following Cardiac Arrest Manifesting as Dyspnoea and Peripheral Oedema in Cardiovascular Multimorbidity: Case Analysis and Brief Literature Review.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13922

Kira Harding, Kate Emblin, Anca Ichim, Daniel Adlington, Rob Daniels, Kinan Mokbel

{"title":"Chronic Kidney Disease Following Cardiac Arrest Manifesting as Dyspnoea and Peripheral Oedema in Cardiovascular Multimorbidity: Case Analysis and Brief Literature Review.","authors":"Kira Harding, Kate Emblin, Anca Ichim, Daniel Adlington, Rob Daniels, Kinan Mokbel","doi":"10.21873/invivo.13922","DOIUrl":"10.21873/invivo.13922","url":null,"abstract":"Background/aim: Chronic kidney disease (CKD) contributes significantly to morbidity, mortality, and healthcare costs. CKD is not only an independent risk factor for cardiovascular disease (CVD) but also a severe complication for patients with CVD, impacting substantially their prognosis and quality of life.Case report: A 79-year-old male with a complex medical history, including asthma, hypertension, myocardial infarction, ischaemic heart disease, and recent atrial fibrillation, presented with new-onset exertional breathlessness and peripheral oedema following cardiac arrest and pacemaker insertion. Investigations, including medication reviews conducted shortly after in an outpatient setting, revealed severe renal impairment with creatinine levels at 250 μmol/l (reference range for adult males: 59-104), representing an initial acute kidney injury (AKI) that did not resolve and resulted in the diagnosis of stage 4 CKD (eGFR 25 ml/min/1.73 m2). The patient was treated with furosemide, dapagliflozin, and adjusted doses of ramipril and edoxaban. Following treatment, the patient's symptoms ameliorated and renal function slightly improved (eGFR 27 ml/min/1.73 m2).Conclusion: This case highlights the importance of individualised treatment for patients with CKD alongside complex cardiovascular multi-morbidity. The administration of dapagliflozin and furosemide, together with careful adjustments to ramipril, were instrumental in stabilising the patient's renal function and alleviating symptoms. This case demonstrates how a multifaceted approach, continuous monitoring, and patient education are essential for achieving optimal outcomes in patients with CKD and cardiovascular comorbidities.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1182-1189"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Hydrogen as an Adjuvant Therapy in Severe Lupus Serositis With Heart Failure: A Case Report on Immune Modulation and Fatigue Reduction.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13924

Yun-Ting Lin, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Hsiao-Chen Liu, Kuang-Yih Wang, Feng-Cheng Liu

{"title":"Molecular Hydrogen as an Adjuvant Therapy in Severe Lupus Serositis With Heart Failure: A Case Report on Immune Modulation and Fatigue Reduction.","authors":"Yun-Ting Lin, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Hsiao-Chen Liu, Kuang-Yih Wang, Feng-Cheng Liu","doi":"10.21873/invivo.13924","DOIUrl":"10.21873/invivo.13924","url":null,"abstract":"Background/aim: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multi-organ inflammation and damage across multiple organs, typically managed with steroids and immunomodulators. However, prolonged use of these treatments is often associated with significant side effects, underscoring the need for adjunctive therapies that improve disease outcomes while minimizing adverse effects. Molecular hydrogen (H2) has demonstrated potential as an antioxidant and anti-inflammatory agent. This report discusses a case of SLE with cardiac complications, evaluating the therapeutic impact of molecular hydrogen therapy on fatigue, immune modulation, and cardiac function.Case report: A 51-year-old female with SLE and acute decompensated heart failure initially received steroids and immunomodulators for disease management. Subsequently, molecular hydrogen therapy was introduced as an adjuvant treatment. Over several months, her cardiac function showed notable improvement, evidenced by reductions in anti-dsDNA and anti-Ro52 antibody levels, and Pro-BNP levels, as well as favorable shifts in T and B cell subsets. Additionally, the patient experienced a significant reduction in fatigue. She successfully tapered off steroids while maintaining disease stability with ongoing molecular hydrogen therapy.Conclusion: This case highlights the potential of molecular hydrogen therapy as an adjuvant treatment in SLE, with observed benefits in immune modulation and fatigue reduction. Further studies are warranted to elucidate its therapeutic role and applicability in autoimmune diseases.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1200-1206"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutaneous Cryosurgery in Dermatology: Evolving Principles and Clinical Applications for Benign, Premalignant, and Malignant Lesions.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13865

Ramia Mokbel, Alevtina Kodresko, Kefah Mokbel, Heba Ghazal, Jon Trembley, Hussam Jouhara

{"title":"Cutaneous Cryosurgery in Dermatology: Evolving Principles and Clinical Applications for Benign, Premalignant, and Malignant Lesions.","authors":"Ramia Mokbel, Alevtina Kodresko, Kefah Mokbel, Heba Ghazal, Jon Trembley, Hussam Jouhara","doi":"10.21873/invivo.13865","DOIUrl":"10.21873/invivo.13865","url":null,"abstract":"Skin and subcutaneous diseases represent a significant public health burden, profoundly impacting quality of life, social interactions, mental health, and daily activities-raising concerns worldwide. In modern cryogenics, cryosurgery is among the therapeutic approaches employed by healthcare professionals to address this broad and complex range of diseases. Over the past four decades, cryosurgery has evolved into a valuable treatment option, used alone or as an adjunct therapy, and is adaptable to the needs of various special populations. This approach offers distinct advantages over established treatments due to its safety, efficiency, feasibility, and cost-effectiveness. However, a comprehensive, up-to-date review of cryosurgery's applications is lacking, which limits research dissemination and recognition among dermatologists. This review aims to provide an overview of cryosurgery principles and its current clinical practice in dermatology, covering a broad range of benign, premalignant, and malignant cutaneous conditions, and highlighting its potential as an essential approach in global healthcare.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"577-612"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fibroma of Tendon Sheath Revisited.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13866

Yuki Shinohara, Jun Nishio, Shizuhide Nakayama, Mikoro Koga, Mikiko Aoki, Takamasa Koga

{"title":"Fibroma of Tendon Sheath Revisited.","authors":"Yuki Shinohara, Jun Nishio, Shizuhide Nakayama, Mikoro Koga, Mikiko Aoki, Takamasa Koga","doi":"10.21873/invivo.13866","DOIUrl":"10.21873/invivo.13866","url":null,"abstract":"Fibroma of tendon sheath (FTS) is a benign fibroblastic/myofibroblastic neoplasm that primarily occurs in the fingers and hands of young and middle-aged adults. The lesion typically presents as a small, firm, slow-growing, painless nodule. Ultrasonography usually shows a focal nodular mass with homogeneous hypoechogenicity. Magnetic resonance imaging reveals a well-defined nodular mass with decreased signal on all pulse sequences. No or minimal peripheral enhancement is often seen after intravenous contrast. Histologically, the lesion is well circumscribed and consists of bland spindle cells in a dense collagenous stroma with slit-like thin-walled vessels at the periphery. A cellular variant of FTS has also been described and shows at least a focal morphological overlap with nodular fasciitis. Immunohistochemistry does not play a significant role in the diagnosis of FTS. Cytogenetic studies have demonstrated the presence of 11q rearrangements. A significant subset of cellular variants of FTS are characterized by ubiquitin specific peptidase 6 (USP6) rearrangements, with a variety of fusion partners. Complete surgical excision is the treatment of choice. This review provides an updated overview of the clinical, radiological, histological, cytogenetic and molecular genetic features of FTS and discusses the differential diagnosis of this uncommon entity.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"613-620"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global, Regional and National Burden of Edentulism and Periodontal Diseases from 1990 to 2021: Analysis of Risk Factors and Prediction of Trends in 2050.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13919

Yong Feng, Liyuan Xiao, Ling-Ling Fu, Martin Gosau, Tobias Vollkommer, Ulrike Speth, Ralf Smeets, Rico Rutkowski, Reinhard E Friedrich, Ming Yan

{"title":"Global, Regional and National Burden of Edentulism and Periodontal Diseases from 1990 to 2021: Analysis of Risk Factors and Prediction of Trends in 2050.","authors":"Yong Feng, Liyuan Xiao, Ling-Ling Fu, Martin Gosau, Tobias Vollkommer, Ulrike Speth, Ralf Smeets, Rico Rutkowski, Reinhard E Friedrich, Ming Yan","doi":"10.21873/invivo.13919","DOIUrl":"10.21873/invivo.13919","url":null,"abstract":"Background/aim: Periodontal diseases and edentulism remain a prevalent and disabling oral health condition worldwide, with significant regional disparities. This study systematically evaluated the burden of periodontal disease and edentulism at global, regional, and national levels from 1990 to 2021, using the Global Burden of Disease (GBD) 2021 framework.Patients and methods: We analyzed trends in incidence, prevalence, and years lived with disability (YLD), exploring their associations with the socio-demographic index (SDI) and other risk factors.Results: The findings reveal considerable variations across SDI regions, with low and low-middle SDI regions experiencing the highest burden. In 2021, the global prevalence of periodontal diseases reached approximately 1.07 billion cases, and the age-standardized incidence and prevalence rates varied significantly by SDI levels. The burden of periodontal disease showed an increasing trend among middle-aged and elderly populations. While sex differences were present in both edentulism and periodontal diseases, they were relatively minor. ARIMA model projections indicate that the burden of edentulism will fluctuate by 2050, while the burden of periodontal diseases will remain stable.Conclusion: This study underscores the need for targeted public health interventions, particularly in resource-limited regions, to improve access to oral healthcare and integrate preventive strategies into broader health initiatives.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1148-1161"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between HLA-B5801 Positivity and Patient Characteristics and Clinical Outcomes in Gout.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13915

Sung Soo Ahn, Jiyoung Agatha Kim, Kunhyung Bae

{"title":"Association Between HLA-B5801 Positivity and Patient Characteristics and Clinical Outcomes in Gout.","authors":"Sung Soo Ahn, Jiyoung Agatha Kim, Kunhyung Bae","doi":"10.21873/invivo.13915","DOIUrl":"10.21873/invivo.13915","url":null,"abstract":"Background/aim: Allopurinol is a standard agent used for lowering uric acid levels. Human leukocyte antigen (HLA)-B5801 positivity increases the incidence of severe cutaneous adverse reactions (SCARs) in allopurinol users. HLA alleles HLA-B27 and HLA-B51 are frequently found in patients with ankylosing spondylitis and Behçet's disease, showing an association with distinct clinical features. In this study, we investigated the association between the HLA-B5801 genotype and patient characteristics and outcomes in gout.Patients and methods: We retrospectively reviewed the medical records of 263 patients with gout who were not receiving uric acid-lowering therapy and were tested for HLA-B5801 positivity between March 2020 and February 2024. Patients were classified according to their HLA-B5801 status, and patient demographics and laboratory variables were compared. The incidence of gout flares or severe flares requiring hospital care within one year was investigated.Results: A total of 37 participants were HLA-B5801 positive (37/263, 14.1%). However, no significant differences were observed in demographic or laboratory variables between the HLA-B5801 positive and negative groups. Subgroup analyses of patients with new-onset gout, males, and those with an estimated glomerular filtration rate ≥60 ml/min/1.73 m2 also demonstrated no significant differences related to HLA-B5801 genotype positivity. The incidence of disease flares or severe flares between patients in the HLA-B5801 positive and negative groups was comparable during the one-year follow-up.Conclusion: Although HLA-B5801 was a significant predictor of allopurinol-associated SCARs, the impact of HLA-B5801 positivity on the clinical characteristics or flares was not evident in this population of patients with gout.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1104-1111"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of PTX3 Genetic Variants With Development of Diabetic Neuropathy.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13874

Yung-Nan Hsu, Ying-Chi Fan, Shih-Chi Su, Lun-Ching Chang, Shun-Fa Yang

{"title":"Association of PTX3 Genetic Variants With Development of Diabetic Neuropathy.","authors":"Yung-Nan Hsu, Ying-Chi Fan, Shih-Chi Su, Lun-Ching Chang, Shun-Fa Yang","doi":"10.21873/invivo.13874","DOIUrl":"10.21873/invivo.13874","url":null,"abstract":"Background/aim: Pentraxin 3 (PTX3), initially discovered as a key player in the defense against infectious pathogens, is crucial for inflammation and tissue regeneration. This study aimed to explore the impact of PTX3 gene variants on the development and progression of diabetic neuropathy (DN).Materials and methods: The potential impact of PTX3 gene variants on the susceptibility to DN was examined by genotyping four single-nucleotide polymorphisms (SNPs) of the PTX3 gene (rs1840680, rs2305619, rs3816527, and rs2120243) in a study involving 730 DN cases and 861 diabetic controls with normal neurologic function.Results: We demonstrated that diabetic subjects homozygous for the minor allele at rs1840680 [AA; adjusted odds ratio (AOR)=1.486; 95% confidence interval (CI)=1.050-2.103; p=0.02] or rs2120243 (AA; AOR=1.483; 95%CI=1.051-2.091; p=0.025) were more likely to develop neurologic complications compared to those homozygous for the corresponding major allele. Further stratification revealed that this correlation with DN risk was observed specifically in males but not in females. In addition, another SNP of the PTX3 gene, rs2305619, was found to be associated with the risk for DN in males (AA vs. GG, AOR=1.686; 95%CI=1.086-2.617, p=0.020), indicating a sex-specific impact of PTX3 gene polymorphisms on damage to the nerves in diabetic patients. Furthermore, DN patients homozygous for the minor allele of rs1840680 (AA), particularly males, had higher levels of LDL-cholesterol than those homozygous for the reference allele (GG) (p=0.034).Conclusion: PTX3 gene polymorphisms are associated with dyslipidemia and nerve damage in diabetic patients in a sex-specific manner.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"702-712"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vivo最新文献